SOUTH JORDAN, Utah, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the expansion of its Maestro Microcatheter product line to now include a new longer length for radial embolization procedures.
The Maestro is part of a comprehensive offering of embolotherapy solutions, which includes Embosphere® Microspheres, the most widely studied and clinically utilized round embolic on the market. Embolization is a minimally invasive procedure that blocks one or more blood vessels or abnormal vascular channels to treat a number of clinical conditions. The new 165-cm Maestro length will be available in 2.1F, 2.4F, 2.8F, and 2.9F catheter diameters to support a broad range of embolization procedures.
“Merit Maestro’s longer length is ideal for radial access,” said Mary Costantino, MD, interventional radiologist at Advanced Vascular Centers in Oregon, and a paid consultant of Merit. “Radial access can streamline patient care by enabling some patients to be treated in outpatient and office-based lab settings where they can return home on the day of their procedure, improving patient satisfaction and saving healthcare resources.”
“The Maestro expansion continues our strong legacy of advancing solutions for our healthcare partners,” said Fred P. Lampropoulos, Merit Medical’s Chairman and CEO. “We are especially pleased to bring new technology to our embolotherapy portfolio. Through ongoing innovation, as well as the reinvention of existing products, we enhance the alignment of our portfolios with our mission of improving lives around the globe.”
The Maestro Microcatheter is compatible with coils up to 0.018" and embolics up to and including 900 µm. Three tip designs are available, including a swan neck designed to seat the catheter in the vessel, reducing the recoiling effect of the microcatheter as embolic is delivered. A hydrophilic coating aids in smooth tracking through tortuous anatomy.
Merit is a market leader in radial access with a portfolio that includes the recently launched PreludeSYNC EZ™ Radial Compression Device, PreludeSYNC Distal™ Radial Compression Device, and Prelude IDeal™ Hydrophilic Sheath Introducer.
Radial artery access is a minimally invasive approach to diagnosing and treating a wide range of medical conditions. Through a small hole in the wrist, a catheter is inserted into the radial artery. Under imaging guidance, the catheter is then threaded through the body’s network of blood vessels to the location needing treatment. Compared to femoral access procedures, or those performed through the femoral artery in the groin, benefits of radial access include fewer bleeding complications, improved patient comfort, and decreased procedure costs.
Learn more about Merit Maestro Microcatheters.
ABOUT MERIT MEDICAL Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,100 people worldwide.
TRADEMARKS Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc., its subsidiaries, or its licensors.
CONTACTS
PR/Media Inquiries
Sarah Comstock
Merit Medical
+1-801-432-2864 | This email address is being protected from spambots. You need JavaScript enabled to view it.
INVESTOR INQUIRIES
Mike Piccinino, CFA, IRC
Westwicke - ICR
+1-443-213-0509 | This email address is being protected from spambots. You need JavaScript enabled to view it.
1. O’Riordan. 2022. “Radial Access for Angiography and PCI on the Rise in the US.” TCTMD (Mar 16). https://www.tctmd.com/news/radial-access-angiography-and-pci-rise-us
Last Trade: | US$101.83 |
Daily Change: | 0.63 0.62 |
Daily Volume: | 289,523 |
Market Cap: | US$5.930B |
November 01, 2024 October 30, 2024 September 17, 2024 September 16, 2024 September 11, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB